Effects of alendronate combined with hormone replacement therapy on osteoporotic postmenopausal Chinese women

Metabolism: Clinical and Experimental

Volumn 55, Issue 6, 2006, Pages 741-747

  Tseng, Li Nien ^a,c   Sheu, Wayne Huey Herng ^a,c   Ho, Esther Shih Chu ^a   Lan, Howard Haw Chang ^a   Hu, Chung Chieh ^a   Kao, Chia Hung ^b  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; CALCIUM CARBONATE; COLLAGEN TYPE 1; CONJUGATED ESTROGEN; CREATININE; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; OSTEOCALCIN; PLACEBO;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BACKACHE; BONE DENSITY; BONE MINERAL; CHINESE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EPIGASTRIC PAIN; ESOPHAGUS DISEASE; ESTROGEN THERAPY; EVALUATION; FEMALE; FEMUR NECK; GASTROINTESTINAL SYMPTOM; HEMOPTYSIS; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SINGLE BLIND PROCEDURE; STROKE; TREATMENT OUTCOME; TREATMENT RESPONSE; VERTEBRA FRACTURE;

AGED; ALENDRONATE; ASIAN CONTINENTAL ANCESTRY GROUP; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COLLAGEN TYPE I; DRUG THERAPY, COMBINATION; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES; SINGLE-BLIND METHOD; TIME FACTORS;

EID: 33646530911     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2006.01.008     Document Type: Article

References (32)

1. Raisz L.G. The osteoporosis revolution. Ann Intern Med 126 (1997) 458-462
2. Tiras M.B., Noyan V., Yildiz A., et al. Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: a prospective, randomized study. Hum Reprod 15 (2000) 2087-2092
3. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 338 (1998) 735-746
4. Fleisch H. Bisphosphonate in osteoporosis: an introduction. Osteoporos Int 3 Suppl (1993) S3-S5
5. Felson D.T., Zhang Y., Hannan M.T., et al. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 329 (1993) 1141-1146
6. Komulainen M., Kroger H., Tuppurainen M.T., et al. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial. Osteoporos Int 11 (2000) 211-218
7. Black D.M., Cummings S.R., Karpf D.B., et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348 (1996) 1535-1541
8. Bone H.G., Downs Jr. R.W., Tucci J.R., et al. Dose-response relationships for alendronate treatment in osteoporotic elderly women. J Clin Endocrinol Metab 82 (1997) 265-274
9. Chesnut III C.H., McClung M.R., Bell N.H., et al. Alendronate treatment of the postmenopausal osteoporotic women: effect of multiple dosages on bone mass and bone remodeling. Am J Med 99 (1995) 144-152
10. Cummings S.R., Black D.M., Thompson D.B., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280 (1998) 2077-2082
11. Ensrud K.B., Black D.M., Palermo L., et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med 157 (1997) 2617-2624
12. Karf D.B., Shapiro D.R., Seeman Jr. E., et al. Prevention of nonvertebral fractures by alendronate: a meta-analysis. JAMA 277 (1997) 1159-1164
13. Liberman U.A., Weiss S.R., Broll J., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333 (1995) 1437-1443
14. McClung M., Cleinniesen B., Daifotis A., et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis: a double-blind, randomized, controlled trial. Ann Intern Med 128 (1998) 253-261
15. Wimalawansa S.C. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 99 (1998) 36-42
16. Lindsay R., Cosman F., Lobo R.A., et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 84 (1999) 3076-3081
17. Palomba S., Orio Jr. F., Colao A., et al. Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically menopausal women with osteoporosis. J Clin Endocrinol Metab 87 (2002) 1502-1508
18. Greenspan S.L., Resnick N.M., and Parker R.A. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA 289 (2003) 2525-2533
19. Greenspan S.L., Resnick N.M., and Parker R.A. Early changes in biochemical marker of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 90 (2005) 2762-2767
20. Tsai K.S., and Tai Y. Epidemiology of osteoporosis in Taiwan. Osteoporos Int 7 Suppl (1997) S96-S98
21. Chang C., Wu P.H., Chang C.H., et al. Hormone levels and menopausal status in middle-aged women: a cross-sectional study. Chin J Public Health 18 (1999) 209-221
22. Tsai K.S., Yen M.L., Pan H.A., et al. Raloxifene versus continuous combined estrogen/progestin therapy: densitometric and biochemical effects in healthy postmenopausal Taiwanese women. Osteoporos Int 12 (2001) 1020-1025
23. Hosking D., Chilvers C.E., Christiansen C., et al. Prevention of bone loss with alendronate in post-menopausal women under 60 years of age. N Engl J Med 338 (1998) 485-492
24. Bone H.G., Greenspan S.L., McKeever C., et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab 85 (2000) 720-726
25. Yen M.L., Yen B.L., Jang M.H., et al. Effects of alendronate on osteopenic postmenopausal Chinese women. Bone 27 (2000) 681-685
26. Lau E.M.C., Woo J., Chan Y.H., et al. Alendronate prevents bone loss in Chinese women with osteoporosis. Bone 27 (2000) 677-680
27. Bell N.H., Bilezikian J.P., Bone III H.G., et al. Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women. J Clin Endocrinol Metab 87 (2002) 2792-2797
28. Wasnich R.D., Ross P.D., Thompson D.E., et al. Skeletal benefits of two years of alendronate treatment are similar for early postmenopausal Asian and Caucasian women. Osteoporos Int 9 (1999) 455-460
29. Evio S., Tiitinen A., Laitinen K., et al. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis. J Clin Endocrinol Metab 89 (2004) 626-631
30. Johnell O., Scheele W.H., Lu Y., et al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87 (2002) 985-992
31. Cummings S.R., Karf D.B., Harris F., et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112 (2002) 281-289
32. Worsfold M., Powell D.E., Jones T.J., et al. Assessment of urinary bone markers for monitoring treatment of osteoporosis. Clin Chem 50 (2004) 2263-2270